Skip to content
OpenCapital
Get started

Biogen BIIB AVONEX — Total Revenue

Other product segments

TYSABRI
$441.5M+15.7%
SPINRAZA
$374M-11.8%
VUMERITY
$179M+29.0%
SKYCLARYS
$150.7M+21.6%
BENEPALI
$122.1M+9.7%
TECFIDERA
$109.5M-46.9%
PLEGRIDY
$64.3M+8.1%
ZURZUVAE
$55.4M+100%
IMRALDI
$49.6M+4.6%
QALSODY
$32.5M+110%
FLIXABI
$10.5M-19.8%
BYOOVIZ
$0-100%
FAMPYRA
$0-100%
FUMADERM And ADUHELM
$0-100%
TOFIDENCE
$0-100%

Similar metrics at other companies

GE HealthCare Technologies logo
GEHCAVS — Total revenues
$1.34B+8.2%
Novavax logo
NVAXNuvaxovid sales — Total Revenue
$9.56M-98.4%
Ligand Pharmaceuticals logo
LGNDCapvaxive — Total revenues and income
$1.97M+122%
Supernus Pharmaceuticals logo
SUPNAPOKYN — Total revenues
$7.73M-48.4%
Incyte logo
INCYJAKAVI — Total revenues
$105.6M+14.7%
Ligand Pharmaceuticals logo
LGNDVaxneuvance — Total revenues and income
$1.61M+25.3%

Other financials

Income statement

See full
Revenue$2.5B+1.9%
Gross profit$1.8B+0.8%
Operating income$610.7M—
Net income$319.5M+32.8%
EPS (diluted)$2.15+31.1%

Balance sheet

See full
Cash & equivalents$3.4B+30.2%
Total debt$6.6B+34.7%
Total equity$18.7B+9.9%
Total assets$29.5B+5.2%

Cash flow

See full
Operating cash flow$645.5M+149%
CapEx$51.2M+38.0%
Free cash flow$594.3M+167%

Valuation

See full
Market cap$31.89B+72.3%
Enterprise value$35.07B+57.0%
P/E22.5×+10.4×
P/S3.2×+1.4×

Profitability

See full
Gross margin75.5%-0.1pp
Operating margin22.9%—
Net margin14.3%-0.8pp
FCF margin24.4%-0.4pp

Returns & leverage

See full
Return on equity8%-1.2pp
Debt / equity0.4×+0.1×
Current ratio3.1×+1.6×

Where this comes from

Reported directly by Biogen in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Biogen’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biogen's avonex — total revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biogen's AVONEX — total revenue?
Biogen (BIIB) reported AVONEX — total revenue of $163.2M in Q1 2026.
How has Biogen's AVONEX — total revenue changed year-over-year?
Biogen's AVONEX — total revenue decreased by 2.2% year-over-year, from $166.8M to $163.2M.
What is the long-term trend for Biogen's AVONEX — total revenue?
Over 4 years (2021 to 2025), Biogen's AVONEX — total revenue has grown at a -12.9% compound annual growth rate (CAGR), from $1.21B to $695.5M.
What does AVONEX — total revenue mean?
This metric represents the total gross sales generated from the specific pharmaceutical product line within the company's multiple sclerosis portfolio. It reflects the market demand, pricing power, and competitive positioning of this legacy therapy as it navigates its product lifecycle. Tracking this revenue is essential for assessing the contribution of mature assets to the company's overall top-line performance.